Donor-derived CD19-CAR T cells post-allogeneic HSCT show that CAR-modified TSCM cells have 2-3x better expansion/persistence, leading to complete responses at low doses, no lymphodepletion needed! PMID:42066750, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00383-1 #Medsky #RNA 🧪
https://www.cell.com/cell/fulltext/S0092-8674(26)00383-1No description availablewww.cell.com